<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; ViroPharma Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/viropharma-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(VPHM) Update on ViroPharma Industrial Facility</title>
		<link>http://www.stockbloghub.com/2012/02/13/vphm-update-on-viropharma-industrial-facility/91534</link>
		<comments>http://www.stockbloghub.com/2012/02/13/vphm-update-on-viropharma-industrial-facility/91534#comments</comments>
		<pubDate>Tue, 14 Feb 2012 04:55:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[PAS]]></category>
		<category><![CDATA[PepsiAmericas Inc.]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91534</guid>
		<description><![CDATA[ViroPharma Inc. (VPHM) recently announced that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Cinryze’s industrial scale manufacturing facility. The regulatory body made three comments related to a portion of the cleaning validation for industrial scale manufacturing, of which only one requires additional unplanned activity. ViroPharma does not expect this activity to take much time to complete. The FDA also said that it has not finished reviewing the company’s January 2012 updated responses to observations specific to the September 2011 inspection of the Amsterdam facility. We note that ViroPharma undertook an expansion of the production capacity for Cinryze in 2009. In early 2010, the company submitted the Cinryze industrial scale manufacturing Prior Approval Supplement (PAS) to the FDA. In October 2010, the regulatory ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/13/vphm-update-on-viropharma-industrial-facility/91534/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VPHM) ViroPharma  Drug Earns Priority Review</title>
		<link>http://www.stockbloghub.com/2012/01/16/vphm-viropharma-drug-earns-priority-review/90265</link>
		<comments>http://www.stockbloghub.com/2012/01/16/vphm-viropharma-drug-earns-priority-review/90265#comments</comments>
		<pubDate>Mon, 16 Jan 2012 23:37:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90265</guid>
		<description><![CDATA[ViroPharma Inc. (VPHM) recently announced that the Canadian regulatory body has granted priority review status to the company’s new drug submission (NDS) for Cinryze. ViroPharma is seeking the drug’s approval for the treatment of prevention, pre-procedure prevention, and treatment of attacks of hereditary angioedema (HAE) in patients who are six years or older. The company expects Health Canada to complete its review of Cinryze in the second half of 2012. We note that Cinryze is currently marketed in the US for the prevention of angioedema attacks in adolescent and adult patients with HAE. In the European Union (EU), the same drug is marketed for the treatment of prevention, pre-procedure prevention, and treatment of attacks of HAE in adolescents and adult patients. We view this development as a positive for ViroPharma, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/16/vphm-viropharma-drug-earns-priority-review/90265/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AA) Company News for January 9, 2012 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2012/01/09/aa-company-news-for-january-9-2012-corporate-summary/89895</link>
		<comments>http://www.stockbloghub.com/2012/01/09/aa-company-news-for-january-9-2012-corporate-summary/89895#comments</comments>
		<pubDate>Mon, 09 Jan 2012 16:34:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Aluminum]]></category>
		<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[AA]]></category>
		<category><![CDATA[Alcoa Inc.]]></category>
		<category><![CDATA[BBY]]></category>
		<category><![CDATA[Best Buy Company Inc]]></category>
		<category><![CDATA[RF Micro Devices Inc.]]></category>
		<category><![CDATA[RFMD]]></category>
		<category><![CDATA[RIG]]></category>
		<category><![CDATA[Transocean Limited]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89895</guid>
		<description><![CDATA[•    After RF Micro Devices Inc. (NASDAQ:RFMD) suggested that its fiscal third quarter revenues might fail to meet analyst’ estimates, its shares declined 19.5% on Friday •    Following Transocean Ltd.’s (NYSE:RIG) announcement that its chief financial officer Ricardo Rosa will be stepping down, shares of the company slipped 1.1% •    Shares of Alcoa, Inc. (NYSE:AA) dropped 2.1% after the company announced plans to shut down or reduce 12% of its global smelting capacity •    ViroPharma Inc. (NASDAQ:VPHM) announced that its is expecting $600 million &#8211; $660 million worth net product sales in 2012 •    Best Buy Co. Inc. (NYSE:BBY) said during the five weeks-period ending December 31, 2011, its same-store sales dropped 1.2% ALCOA INC (AA): Free Stock Analysis Report BEST BUY (BBY): Free Stock Analysis Report RF MICRO DEVICE ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/09/aa-company-news-for-january-9-2012-corporate-summary/89895/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals Dificlir Cleared in European Union</title>
		<link>http://www.stockbloghub.com/2011/12/15/optr-optimer-pharmaceuticals-dificlir-cleared-in-european-union/88596</link>
		<comments>http://www.stockbloghub.com/2011/12/15/optr-optimer-pharmaceuticals-dificlir-cleared-in-european-union/88596#comments</comments>
		<pubDate>Thu, 15 Dec 2011 10:00:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CDI]]></category>
		<category><![CDATA[CDI Corporation]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88596</guid>
		<description><![CDATA[Optimer Pharmaceuticals, Inc. (OPTR) and partner Astellas Pharma recently announced that their antibiotic Dificlir received approval in the European Union (EU), not belying expectations. The European Medicines Agency (EMA) cleared Dificlir for the treatment of clostridium difficile-associated diarrhea (CDAD) also known as clostridium difficile infection (CDI). CDAD is the most common nosocomial or hospital-acquired diarrhea and is a significant malaise in hospitals and nursing home facilities. The EU approval does not surprise us since in September this year Dificlir received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the EMA. Dificlir is already marketed as Dificid in the US for CDAD in partnership with Cubist Pharmaceuticals, Inc. (CBST). The European regulatory body’s decision was based on data from two late stage studies which showed ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/15/optr-optimer-pharmaceuticals-dificlir-cleared-in-european-union/88596/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals Moved Down to Neutral</title>
		<link>http://www.stockbloghub.com/2011/12/14/optr-optimer-pharmaceuticals-moved-down-to-neutral/87901</link>
		<comments>http://www.stockbloghub.com/2011/12/14/optr-optimer-pharmaceuticals-moved-down-to-neutral/87901#comments</comments>
		<pubDate>Wed, 14 Dec 2011 20:48:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87901</guid>
		<description><![CDATA[We recently downgraded our rating on Optimer Pharmaceuticals Inc. (OPTR) to Neutral from Outperform as we await more visibility on how the commercial launch of its sole marketed antibiotic Dificid (fidaxomicin) takes shape. Optimer launched Dificid in July 2011 in the US for the treatment of clostridium difficile-associated diarrhea (CDAD). CDAD is the most common nosocomial or hospital-acquired diarrhea and is a significant malaise in hospitals and nursing home facilities.  Dificid (twice daily tablets) is the first drug to be approved in almost 30 years for the treatment of CDAD. Dificid scores better than currently available treatment options on many parameters. Dificid has been shown to be non-inferior to ViroPharma’s (VPHM) Vancocin (the only other FDA approved antibiotic for the treatment of clostridium difficile infection) in late stage studies in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/14/optr-optimer-pharmaceuticals-moved-down-to-neutral/87901/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VPHM) ViroPharma Going Strong</title>
		<link>http://www.stockbloghub.com/2011/11/04/vphm-viropharma-going-strong/86191</link>
		<comments>http://www.stockbloghub.com/2011/11/04/vphm-viropharma-going-strong/86191#comments</comments>
		<pubDate>Fri, 04 Nov 2011 18:37:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86191</guid>
		<description><![CDATA[ViroPharma Inc. (VPHM) posted third quarter 2011 earnings (including special items) of 35 cents per share, surpassing the Zacks Consensus Estimate of 33 cents, but lower than the year-ago figure of 45 cents. Excluding special items, but including stock based compensation expense, earnings came in at 52 cents per share for the third quarter, reflecting an increase of 8.3%. Higher revenues and lower share count helped boost earnings. Revenues Higher sales from Cinryze helped improve quarterly revenues to $143.0 million, from $117.8 million reported in the year-ago quarter. Revenues also beat the Zacks Consensus Estimate of $131.0 million. Cinryze sales increased 33.2% to $65.4 million during the reported quarter, and Vancocin sales came in at $76.6 million, reflecting an increase of 13.3%. While the increase in Cinryze sales was due ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/04/vphm-viropharma-going-strong/86191/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VPHM) ViroPharma and Halozyme Therapeutics Begin Trial</title>
		<link>http://www.stockbloghub.com/2011/09/19/vphm-viropharma-and-halozyme-therapeutics-begin-trial/83259</link>
		<comments>http://www.stockbloghub.com/2011/09/19/vphm-viropharma-and-halozyme-therapeutics-begin-trial/83259#comments</comments>
		<pubDate>Mon, 19 Sep 2011 20:40:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83259</guid>
		<description><![CDATA[ViroPharma Inc. (VPHM) and its partner Halozyme Therapeutics (HALO) recently announced the initiation of a mid-stage trial on its drug Cinryze. The phase II study is designed to evaluate the safety, and pharmacokinetics and pharmacodynamics of the subcutaneous formulation of Cinryze in combination with Halozyme&#8217;s Enhanze technology, in patients suffering from hereditary angioedema (HAE). Cinryze in the intravenous form is currently marketed worldwide as a treatment for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. The Enhanze technology is a proprietary drug-delivery platform, using Halozyme&#8217;s recombinant human hyaluronidase enzyme (rHuPH20). This proprietary rHuPH20 enzyme facilitates the absorption and dispersion of drugs or fluids that are injected under the skin. The initiation of the trial triggered a milestone payment of $3 million from ViroPharma to Halozyme. This ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/19/vphm-viropharma-and-halozyme-therapeutics-begin-trial/83259/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VPHM) ViroPharma Quarterly Earnings Report Misses Due to Higher Expenses</title>
		<link>http://www.stockbloghub.com/2011/08/03/vphm-viropharma-quarterly-earnings-report-misses-due-to-higher-expenses/80406</link>
		<comments>http://www.stockbloghub.com/2011/08/03/vphm-viropharma-quarterly-earnings-report-misses-due-to-higher-expenses/80406#comments</comments>
		<pubDate>Wed, 03 Aug 2011 15:34:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80406</guid>
		<description><![CDATA[ViroPharma Inc. (VPHM) posted second quarter fiscal 2011 earnings of 36 cents per share, missing the Zacks Consensus Estimate by 3 cents and the year-ago figure by a penny. Despite higher revenues, earnings bore the brunt of increased operating expenses. Revenues Higher sales from Cinryze boosted the quarterly revenues from $109.0 million in the year-ago quarter to $128.8 million. However, revenues fell shy of the Zacks Consensus Estimate of $131.0 million. Cinryze sales increased 55.1% to $62.5 million during the reported quarter, while Vancocin sales came in at $65.2 million, reflecting a slide of 4.7%. The increase in Cinryze sales was due to higher patient demand. On the other hand, Vancocin sales were negatively impacted by declining volume, partly offset by price rise. Other Details Research and development (R&#38;D) expenses ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/03/vphm-viropharma-quarterly-earnings-report-misses-due-to-higher-expenses/80406/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals Analyst Maintains Neutral</title>
		<link>http://www.stockbloghub.com/2011/07/05/optr-optimer-pharmaceuticals-analyst-maintains-neutral/78351</link>
		<comments>http://www.stockbloghub.com/2011/07/05/optr-optimer-pharmaceuticals-analyst-maintains-neutral/78351#comments</comments>
		<pubDate>Wed, 06 Jul 2011 00:16:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SLXP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78351</guid>
		<description><![CDATA[We have maintained a Neutral rating on Optimer Pharmaceuticals, Inc. (OPTR) with a target price of $12.00 per share. We find the US Food and Drug Administration’s (FDA) approval of Optimer’s first drug, antibiotic Dificid, for the treatment of clostridium difficile-associated diarrhea (CDAD), highly encouraging. CDAD is the most common nosocomial or hospital-acquired diarrhea and is a significant malaise in hospitals and nursing home facilities. Dificid (twice daily tablets) is the first drug to be approved in almost 30 years for the treatment of CDAD. Dificid is the only drug which has shown superiority over ViroPharma’s (VPHM) Vancocin &#8211; the only other FDA approved antibiotic for the treatment of clostridium difficile infection &#8211; in sustaining clinical response for CDAD. The superior recurring benefits of Dificid over Vancocin will be included ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/05/optr-optimer-pharmaceuticals-analyst-maintains-neutral/78351/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CHMP) ViroPharma&#8217;s Epilepsy Drug Recommended</title>
		<link>http://www.stockbloghub.com/2011/06/28/chmp-viropharmas-epilepsy-drug-recommended/77702</link>
		<comments>http://www.stockbloghub.com/2011/06/28/chmp-viropharmas-epilepsy-drug-recommended/77702#comments</comments>
		<pubDate>Tue, 28 Jun 2011 20:02:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Business Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[AMR]]></category>
		<category><![CDATA[AMR Corporation]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77702</guid>
		<description><![CDATA[The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recently gave the go ahead to ViroPharma Inc.’s (VPHM) Buccolam (midazolam, oromucosal solution). The company is seeking approval for Buccolam to be used as a treatment for prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less than 18 years. The European Commission’s (EC) decision on ViroPharma’s Pediatric Use Marketing Authorization (PUMA) for Buccolam is expected by the fourth quarter of 2011, which will also make the candidate the first product to gain approval under the centralized PUMA procedure. PUMA is a new type of centralized marketing authorization procedure for medicines that are developed specifically for children and may already be approved for other indications or routes of administration in adults. ViroPharma’s ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/28/chmp-viropharmas-epilepsy-drug-recommended/77702/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VPHM) ViroPharma&#8217;s HAE Drug Gets EU Nod</title>
		<link>http://www.stockbloghub.com/2011/06/16/vphm-viropharmas-hae-drug-gets-eu-nod/76542</link>
		<comments>http://www.stockbloghub.com/2011/06/16/vphm-viropharmas-hae-drug-gets-eu-nod/76542#comments</comments>
		<pubDate>Thu, 16 Jun 2011 15:20:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMR]]></category>
		<category><![CDATA[AMR Corporation]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76542</guid>
		<description><![CDATA[ViroPharma Inc. (VPHM) recently announced that the European Commission (EC) granted Centralized Marketing Authorization to Cinryze for the treatment of hereditary angioedema (HAE). The drug is indicated for the treatment of pre-procedure prevention of angioedema attacks in adults and adolescents with HAE, and routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of HAE, who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment. The EC’s approval of Cinryze does not come as a surprise, as in March the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had recommended it. We note that in May, ViroPharma had entered into a global licensing deal with Halozyme Therapeutics, Inc. (HALO), ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/16/vphm-viropharmas-hae-drug-gets-eu-nod/76542/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-on-shares-2/76322</link>
		<comments>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-on-shares-2/76322#comments</comments>
		<pubDate>Wed, 15 Jun 2011 03:24:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HAP]]></category>
		<category><![CDATA[Market Vectors RVE Hard Assets Prod ETF]]></category>
		<category><![CDATA[Neenah Paper Inc.]]></category>
		<category><![CDATA[NP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76322</guid>
		<description><![CDATA[We have maintained our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $24.00 per share following the announcement of first quarter 2011 financial results. Theravance’s first quarter 2011 loss per share of 28 cents was in line with the Zacks Consensus Estimate, but narrower than the year-ago loss of 35 cents per share. Revenues at Theravance increased 10% year over year to $6.3 million. An increase in royalty revenues from Vibativ sales in the reported quarter was attributable for both the jump in revenues and the narrower year-over-year loss per share. However, total revenue was below the Zacks Consensus Revenue Estimate of $7 million. Theravance has active collaborations with GlaxoSmithKline (GSK) for the Relovair, LAMA/LABA (also called 719/VI) and MABA programs. The Relovair program holds the biggest ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-on-shares-2/76322/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-rating-on-shares/76253</link>
		<comments>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-rating-on-shares/76253#comments</comments>
		<pubDate>Tue, 14 Jun 2011 15:03:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HAP]]></category>
		<category><![CDATA[Market Vectors RVE Hard Assets Prod ETF]]></category>
		<category><![CDATA[Neenah Paper Inc.]]></category>
		<category><![CDATA[NP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76253</guid>
		<description><![CDATA[We have maintained our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $24.00 per share following the announcement of first quarter 2011 financial results. Theravance’s first quarter 2011 loss per share of 28 cents was in line with the Zacks Consensus Estimate, but narrower than the year-ago loss of 35 cents per share. Revenues at Theravance increased 10% year over year to $6.3 million. An increase in royalty revenues from Vibativ sales in the reported quarter was attributable for both the jump in revenues and the narrower year-over-year loss per share. However, total revenue was below the Zacks Consensus Revenue Estimate of $7 million. Theravance has active collaborations with GlaxoSmithKline (GSK) for the Relovair, LAMA/LABA (also called 719/VI) and MABA programs. The Relovair program holds the biggest ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-rating-on-shares/76253/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharma Beats on One-Time Gain</title>
		<link>http://www.stockbloghub.com/2011/05/10/optr-optimer-pharma-beats-on-one-time-gain/73730</link>
		<comments>http://www.stockbloghub.com/2011/05/10/optr-optimer-pharma-beats-on-one-time-gain/73730#comments</comments>
		<pubDate>Wed, 11 May 2011 05:28:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CDI]]></category>
		<category><![CDATA[CDI Corporation]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SLXP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73730</guid>
		<description><![CDATA[Optimer Pharma’s (OPTR) first quarter 2011 earnings of $1.14 per share tellingly reversed the year-ago loss of 39 cents per share and exceeded the Zacks Consensus Estimate of 30 cents. The earnings beat was due to a huge increase in the top-line in the reported quarter. In the first quarter, revenues were $69.3 million versus $0.30 million in the prior-year quarter. Optimer does not have any marketed products at present. The substantial year-over-year growth was due to the receipt of a one-time $69.2 million upfront payment from Astellas Pharma in exchange for development and commercialization rights for fidaxomicin in certain territories outside US. Fidaxomicin is Optimer’s primary drug candidate which is currently under review both in the US and Europe for the treatment of Clostridium difficile infection (CDI). Fidaxomicin will ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/10/optr-optimer-pharma-beats-on-one-time-gain/73730/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals Partners With Cubist Pharmaceuticals for Dificid</title>
		<link>http://www.stockbloghub.com/2011/04/07/optr-optimer-pharmaceuticals-partners-with-cubist-pharmaceuticals-for-dificid/70927</link>
		<comments>http://www.stockbloghub.com/2011/04/07/optr-optimer-pharmaceuticals-partners-with-cubist-pharmaceuticals-for-dificid/70927#comments</comments>
		<pubDate>Thu, 07 Apr 2011 17:24:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CDI]]></category>
		<category><![CDATA[CDI Corporation]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SLXP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70927</guid>
		<description><![CDATA[Optimer Pharmaceuticals Inc. (OPTR) recently announced an exclusive two-year agreement with Cubist Pharmaceuticals Inc. (CBST) to co-promote its lead pipeline candidate, fidaxomicin, to be sold as Dificid in the US. The collaboration follows on the heels of a US panel backing for Dificid for the treatment of Clostridium difficile infection (CDI), which is also known as Clostridium difficile-associated diarrhea (CDAD). The FDA decision on Dificid is expected in May 2011. The candidate is also under regulatory review in the EU. Per the terms of the deal, Optimer will book sales on the candidate, if approved. Optimer also retains the new drug application (NDA) for Dificid. It will also be responsible for FDA approval and manufacturing of the candidate. In exchange for its efforts in co-promoting Dificid, Cubist will be entitled ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/07/optr-optimer-pharmaceuticals-partners-with-cubist-pharmaceuticals-for-dificid/70927/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals Earns FDA Panel Nod on Dificid Drug</title>
		<link>http://www.stockbloghub.com/2011/04/07/optr-optimer-pharmaceuticals-earns-fda-panel-nod-on-dificid-drug/70818</link>
		<comments>http://www.stockbloghub.com/2011/04/07/optr-optimer-pharmaceuticals-earns-fda-panel-nod-on-dificid-drug/70818#comments</comments>
		<pubDate>Thu, 07 Apr 2011 14:10:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CDI]]></category>
		<category><![CDATA[CDI Corporation]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SLXP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70818</guid>
		<description><![CDATA[Optimer Pharmaceuticals Inc. (OPTR) received a major boost when an advisory panel of the US Food and Drug Administration (FDA) unanimously recommended approval of its lead pipeline candidate, Dificid (fidaxomicin), for the treatment of Clostridium difficile infection (CDI) and for reducing the risk of recurrence when used for treatment of initial CDI. CDI is the most common nosocomial or hospital-acquired diarrhea. The Anti-Infective Drugs Advisory Committee (AIDAC) voted 13-0 to recommend approval of the candidate believing that it was safe and efficacious in the treatment of CDI. The positive recommendation was based on combined data from two late-stage studies, which revealed that Dificid was superior to ViroPharma’s (VPHM) Vancocin (the only FDA approved antibiotic for the treatment of CDI) in reducing CDI recurrence by 47%. The data further revealed improved ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/07/optr-optimer-pharmaceuticals-earns-fda-panel-nod-on-dificid-drug/70818/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/04/02/thrx-theravance-analyst-maintains-neutral-on-shares/70204</link>
		<comments>http://www.stockbloghub.com/2011/04/02/thrx-theravance-analyst-maintains-neutral-on-shares/70204#comments</comments>
		<pubDate>Sat, 02 Apr 2011 15:18:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70204</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $25.00 after the company&#8217;s fourth quarter and fiscal year 2010 financial results. Theravance’s fourth quarter 2010 loss per share of 25 cents was narrower than both the Zacks Consensus Estimate for a loss of 28 cents and the year-ago loss of 35 cents per share. The earnings improvement was driven by a better top-line performance and lower research and development costs. Revenue at Theravance increased more than 80% over the prior year to $6.9 million. Revenue was also slightly above the Zacks Consensus Revenue Estimate of $6 million. Theravance has active collaborations with GlaxoSmithKline (GSK) for the Relovair, LAMA/LABA (also called 719/VI) and MABA programs. The Relovair program holds the biggest potential in the company’s pipeline, which ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/02/thrx-theravance-analyst-maintains-neutral-on-shares/70204/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals Signs Manufacturing Deal</title>
		<link>http://www.stockbloghub.com/2010/05/25/optr-optimer-pharmaceuticals-signs-manufacturing-deal/38389</link>
		<comments>http://www.stockbloghub.com/2010/05/25/optr-optimer-pharmaceuticals-signs-manufacturing-deal/38389#comments</comments>
		<pubDate>Tue, 25 May 2010 22:15:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CDI]]></category>
		<category><![CDATA[CDI Corporation]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SLXP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=38389</guid>
		<description><![CDATA[Recently, Optimer Pharmaceuticals (OPTR) entered into a long-term supply agreement with India based Biocon Limited. The agreement is aimed at manufacturing the active pharmaceutical ingredient of fidaxomicin, Optimer’s lead candidate. Fidaxomicin is being developed to treat Clostridium difficile infection (CDI), the most common nosocomial or hospital-acquired, diarrhea. Following positive results from the second phase III trial of the drug in February 2010, Optimer is preparing to submit a new drug application in the second half of 2010. We believe the agreement with Biocon is a step towards the preparatory groundwork. While Optimer currently holds worldwide rights to fidaxomicin, it is on the lookout for a suitable partnership for the commercialization of fidaxomicin outside North America. Optimer also plans to submit a Marketing Authorization Application (MAA) for fidaxomicin with the European ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/25/optr-optimer-pharmaceuticals-signs-manufacturing-deal/38389/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals Reports Positive Phase III Data</title>
		<link>http://www.stockbloghub.com/2010/04/12/optr-optimer-pharmaceuticals-reports-positive-phase-iii-data/33422</link>
		<comments>http://www.stockbloghub.com/2010/04/12/optr-optimer-pharmaceuticals-reports-positive-phase-iii-data/33422#comments</comments>
		<pubDate>Mon, 12 Apr 2010 17:24:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CDI]]></category>
		<category><![CDATA[CDI Corporation]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33422</guid>
		<description><![CDATA[Recently, Optimer Pharmaceuticals (OPTR) presented positive data from a final stage trial of one of its lead candidates, fidaxomicin. The second phase III study was conducted in patients with Clostridium difficile infection (CDI). The data were presented at the 20th Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Vienna, Austria. The phase III trial, conducted in two phases enrolled over 1,100 patients. The second phase III trial, conducted in about 100 clinical sites in North America and Europe with 535 patients, was aimed at comparing the safety and effectiveness of fidaxomicin with that of Vancocin. It was observed that fidaxomicin met the primary endpoint of non-inferiority compared to Vancocin. Moreover, fidaxomicin scored better than Vancocin on both recurrence rates and global cure rates. We note that these ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/12/optr-optimer-pharmaceuticals-reports-positive-phase-iii-data/33422/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VPHM) ViroPharma Begins Study Of Durg For Treating Angioedema in Children</title>
		<link>http://www.stockbloghub.com/2010/04/06/vphm-viropharma-begins-study-of-durg-for-treating-angioedema-in-children/32922</link>
		<comments>http://www.stockbloghub.com/2010/04/06/vphm-viropharma-begins-study-of-durg-for-treating-angioedema-in-children/32922#comments</comments>
		<pubDate>Tue, 06 Apr 2010 20:45:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32922</guid>
		<description><![CDATA[Recently, ViroPharma Inc. (VPHM) announced the initiation of a mid-stage study to evaluate Cinryze (C1 Esterase Inhibitor (Human)) for treating acute angioedema attacks in children (n=12) suffering from hereditary angioedema (HAE). A child has an even probability of being affected with hereditary angioedema if a parent suffers from HAE since it is an autosomal dominant disease. HAE is a rare, severely debilitating, fatal genetic disease caused by the deficiency of C1 inhibitor, a human plasma protein. The design of the single-dose, open-label study was agreed with the Pediatric Committee of the European Medicines Agency. The agreement was part of the Pediatric Investigational Plan approved before ViroPharma’s submission of a Marketing Authorization Application (MAA) for European approval of Cinryze. The company is seeking European approval of the drug for the prevention ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/06/vphm-viropharma-begins-study-of-durg-for-treating-angioedema-in-children/32922/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Johnson and Johnson Suffers Another Pipeline Setback</title>
		<link>http://www.stockbloghub.com/2009/12/31/jnj-johnson-and-johnson-suffers-another-pipeline-setback/24014</link>
		<comments>http://www.stockbloghub.com/2009/12/31/jnj-johnson-and-johnson-suffers-another-pipeline-setback/24014#comments</comments>
		<pubDate>Thu, 31 Dec 2009 18:24:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24014</guid>
		<description><![CDATA[Johnson and Johnson (JNJ) has received yet another setback related to its pipeline candidate ceftobiprole, a broad-spectrum antibiotic ? aiming the methicillin-resistant Staphylococcus aureus (MRSA) ? for the treatment of complicated skin infections and nosocomial pneumonia. Johnson and Johnson had licensed the drug from Swiss drug company Basilea Pharmaceuticals in 2005. Johnson and Johnson received a complete response letter (CRL) from the US Food and Drug Administration (FDA), delaying the approval process further. According to the FDA, there were many flaws in the trials due to which the company has been asked to conduct new studies to evaluate the drug&#8217;s safety and effectiveness. Johnson and Johnson intends to discuss its future course of action related to ceftobiprole with the FDA shortly. The new drug application (NDA) for ceftobiprole has been ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/31/jnj-johnson-and-johnson-suffers-another-pipeline-setback/24014/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Earns Milestone Payment</title>
		<link>http://www.stockbloghub.com/2009/10/26/thrx-theravance-earns-milestone-payment/18785</link>
		<comments>http://www.stockbloghub.com/2009/10/26/thrx-theravance-earns-milestone-payment/18785#comments</comments>
		<pubDate>Mon, 26 Oct 2009 23:39:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18785</guid>
		<description><![CDATA[Recently, Theravance (THRX) received a milestone payment of $20 million from its partner Astellas Pharma. The payment follows the U.S. Food and Drug Administration (FDA) approval of Vibativ (telavancin) and for supplying Astellas Pharma with the launch inventory for the first commercial sale of the drug in the U.S. Vibativ is expected to hit the U.S. market by year-end. Earlier, in September, Theravance received FDA approval to market Vibativ for the treatment of complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria. While the drug will be marketed and sold by Astellas, Theravance will receive royalties on global sales. In the U.S. , the company will help Astellas in marketing the drug for the first three years post approval. Apart from cSSSI, Vibativ is also being studied for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/26/thrx-theravance-earns-milestone-payment/18785/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis Acquires Antibiotic Rights</title>
		<link>http://www.stockbloghub.com/2009/10/09/nvs-novartis-acquires-antibiotic-rights/17329</link>
		<comments>http://www.stockbloghub.com/2009/10/09/nvs-novartis-acquires-antibiotic-rights/17329#comments</comments>
		<pubDate>Fri, 09 Oct 2009 17:28:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17329</guid>
		<description><![CDATA[Today, Novartis (NVS) acquired exclusive worldwide rights to PTK 0796, a broad spectrum antibiotic from a privately held company, Paratek Pharmaceuticals. The drug is meant for the treatment of infections caused by drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumoniae (MDRSP). PTK 0796, being a broad spectrum antibiotic, could be used as a single agent against a range of bacteria unlike other antibiotics, which may have to be used in combination. Although we are yet to know the exact financial terms of the deal, Novartis will be making an upfront payment to Paratek in addition to future milestone payments and royalties. Both the companies will share the costs and responsibilities related to the drug’s development. A phase III trial for the drug is being conducted ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/09/nvs-novartis-acquires-antibiotic-rights/17329/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

